The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)

N/AUnknownNCT01020253

Yokohama City University Medical Center60 enrolled

Overview

The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective on prosthetic or lumbar spine BMD after total hip arthroplasty.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Bone Density Arthroplasty, Replacement, Hip

Interventions

alendronate, alfacalcidolDRUG

Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.

Eligibility

Sex: ALLMin age: 44 YearsMax age: 82 Years

Medical Language ↔ Plain English

Inclusion Criteria: * osteoarthritis of the hip * patients after total hip arthroplasty Exclusion Criteria: * diseases related to bone metabolism * patients taking drugs which affect bone metabolism

Locations (1)

Department of orthopaedic surgery, Yokohama City University

Yokohama, Kanagawa, Japan

Outcomes

Primary Outcomes

DEXA QDR 2000, Hologic Co.

Time frame: 1, 12, 24 and 48 weeks after operation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.